Rockefeller Capital Management L.P. Has $32.05 Million Stake in Cencora, Inc. (NYSE:COR)

Rockefeller Capital Management L.P. grew its stake in Cencora, Inc. (NYSE:COR - Free Report) by 22.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 142,650 shares of the company's stock after acquiring an additional 26,530 shares during the quarter. Rockefeller Capital Management L.P. owned 0.07% of Cencora worth $32,051,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of COR. Passumpsic Savings Bank boosted its position in shares of Cencora by 4.9% during the third quarter. Passumpsic Savings Bank now owns 6,464 shares of the company's stock worth $1,455,000 after purchasing an additional 304 shares in the last quarter. Virtu Financial LLC grew its stake in Cencora by 112.2% in the third quarter. Virtu Financial LLC now owns 10,227 shares of the company's stock valued at $2,302,000 after acquiring an additional 5,407 shares during the period. World Investment Advisors LLC bought a new stake in shares of Cencora in the third quarter worth about $4,072,000. Arvest Bank Trust Division bought a new position in shares of Cencora during the 3rd quarter valued at about $218,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Cencora in the 3rd quarter valued at approximately $566,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company boosted their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Finally, Bank of America increased their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $284.55.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. The trade was a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,675 shares of company stock worth $8,034,778. Company insiders own 10.80% of the company's stock.

Cencora Stock Performance

Shares of COR traded up $2.58 during mid-day trading on Friday, reaching $287.02. The company's stock had a trading volume of 1,617,494 shares, compared to its average volume of 1,509,017. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock has a market cap of $55.66 billion, a P/E ratio of 40.83, a PEG ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. The business has a 50-day simple moving average of $264.00 and a two-hundred day simple moving average of $246.97.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.